Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for KT-579 in Inflammatory disorders. The expected timing is based on the latest available company guidance and may change.
5/9/25- Ongoing IND enabling studies w/ Ph1 testing to begin in early 2026. 11/04/25:- Completed IND-enabling studies; KT-579 entering Ph1 in early 2026 with supportive preclinical efficacy data. 02/27/26:- Dosing started in Ph1 healthy volunteer trial; data expected in H2 2026. 04/30/26:- Ph1 healthy volunteer trial ongoing; data H2 2026; lupus and IBD data presentations planned at DDW, EULAR, FOCIS 2026. 05/05/26:- DDW 2026 poster showed preclinical IBD activity. Phase 1 healthy-volunteer data expected H2 2026. 08/05/26:- Ph1 data expected Q4 2026. Lupus Ph1b planned after healthy-volunteer trial.
Verification
Confirm timing and program details against the company announcement or filing.